Quidelortho CORP

QuidelOrtho Corporation announced the results of its 2026 Annual Meeting of Stockholders, including the election of ten directors and the ratification of its independent auditor.

QuidelOrtho announced first quarter 2026 financial results, reporting $620 million in total revenue, and updated its full-year 2026 financial guidance.

QuidelOrtho announced preliminary Q1 2026 revenue of $615-$620 million, citing a weak respiratory season and geopolitical disruptions.

QuidelOrtho Corporation announced the retirement of its Chief Legal Officer, Michelle A. Hodges, and the appointment of Nathaniel Sisitsky as her successor, effective March 23, 2026.

QuidelOrtho Corporation's Chief Financial Officer, Joseph M. Busky, will retire effective June 30, 2026, for personal reasons.

QuidelOrtho announced its fourth quarter and full-year 2025 financial results, highlighting growth in core diagnostics and significant margin expansion, alongside a positive outlook for 2026.

QuidelOrtho Corporation reported a significant net loss in the third quarter of 2025, primarily driven by a $700.7 million goodwill impairment charge and ongoing restructuring efforts.

QuidelOrtho Corporation reported a significant net loss in Q2 2025, driven by restructuring charges and a decline in total revenues, despite some growth in core business units.

QuidelOrtho's Q1 2025 revenue decreased by 3% year-over-year to $692.8 million, impacted by U.S. donor screening wind-down and fluctuating respiratory product demand.

QuidelOrtho Corporation reported a significant net loss of $1.87 billion for the third quarter of 2024, primarily due to a substantial goodwill impairment charge.

QuidelOrtho's Q2 2024 results reveal a substantial goodwill impairment charge and a decrease in revenue compared to the previous year.

QuidelOrtho Corporation reported a significant net loss of $1.7 billion for the first quarter of 2024, primarily due to a substantial goodwill impairment charge.

QuidelOrtho's 2024 10-K filing highlights strategic shifts including a U.S. donor screening portfolio wind-down and responses to competitive pressures in the diagnostics market.

QuidelOrtho Corporation files an amendment to its 2023 annual report to include additional details under Critical Audit Matters, while reaffirming its unqualified opinion on the financial statements.

QuidelOrtho Corporation's 2023 annual report highlights a year of strategic integration following the merger, with a focus on R&D, global expansion, and navigating a changing diagnostics market.

Micah W Young, Chief Financial Officer of QuidelOrtho Corp, received 356,555 shares of common stock on July 15, 2026.

Bryan Michael Hanson, EVP Global Port. Mgmt & Mkting at QuidelOrtho Corp, reported transactions involving common stock and restricted stock units.

QuidelOrtho Corp. director Kenneth J. Widder received a significant equity grant comprising restricted stock units, with vesting schedules extending into 2027.

QuidelOrtho Corp reports a grant of restricted stock units to Director R. Scott Huennekens.

John R. Chiminski, a Director at QuidelOrtho Corp, was granted restricted stock units as compensation for services.

Joseph D. Wilkins Jr., a Director at QuidelOrtho Corp, was granted 15,532 restricted stock units on June 25, 2026, which are set to vest on June 25, 2027.

QuidelOrtho Corporation has announced its 2026 Annual Meeting of Stockholders, scheduled for June 16, 2026, to be held virtually.

QuidelOrtho Corporation has filed a definitive proxy statement with the SEC.

QuidelOrtho's proxy statement details proposals for the 2025 annual meeting, including the election of directors, approval of an equity incentive plan, and ratification of the independent auditor.

QuidelOrtho Corporation has filed a definitive proxy statement with the SEC.

QuidelOrtho's proxy statement details the agenda for the upcoming annual meeting, including director elections, executive compensation, and auditor ratification.

Neuberger Berman Group LLC and its affiliates have reported beneficial ownership of 5.2% of QuidelOrtho Corp's common stock as of June 30, 2026.

FMR LLC, through its subsidiaries, has reported a beneficial ownership of 11.5% of QuidelOrtho Corp's common stock as of April 30, 2026.

Invesco Ltd. has filed an amendment to its Schedule 13G, disclosing a 4.6% beneficial ownership stake in QuidelOrtho Corp.

Newtyn Management, LLC and its affiliate Newtyn TE Partners, LP have filed an amended Schedule 13G, reporting a combined beneficial ownership of 7.8% of QuidelOrtho Corporation's common stock.

Newtyn Management, LLC has reported beneficial ownership of 4,558,472 shares, representing 6.7% of QuidelOrtho Corporation's common stock as of March 31, 2026.

FMR LLC, along with Abigail P. Johnson, has filed a Schedule 13G, reporting beneficial ownership of 9.7% of QuidelOrtho Corp's common stock as of March 31, 2026.